If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
This license will enable Abbott to enhance access to this novel therapy to more patients across India
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
Secretary Vaidya Rajesh Kotecha has urged senior officials to strive for the successful attainment of targets during the campaign
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
Agreement further expands Aptar Pharma’s leading respiratory portfolio
Subscribe To Our Newsletter & Stay Updated
